Zeo ScientifiX, Inc. (ZEOX) said it could not complete the compilation, dissemination and review of its Transition Report on Form 10-KT for the eight months ended June 30, 2026, by September 28, 2026, without undue hardship and expense. The company anticipates filing the report within the applicable “grace” period under Securities Exchange Act Rule 12b-25.
Zeo ScientifiX, Inc. (ZEOX) has changed its fiscal year end from October 31 to June 30, effective for the fiscal year ending June 30, 2026. This change was approved by the Board of Directors and became effective on September 10, 2026.
The transition period created by this change is the eight-month period from November 1, 2025 through June 30, 2026. Zeo ScientifiX plans to file a transition report on Form 10-KT covering this transition period, within the time period required by applicable Securities and Exchange Commission rules.
Zeo ScientifiX, Inc. (ZEOX) reported that it plans to expand its commercial and provider-support presence into Georgia and Tennessee, aligning with newly enacted state laws that establish frameworks for certain stem cell and regenerative medicine therapies. The company intends to support healthcare professionals with regenerative biologics, scientific resources, physician education, and operational guidance tailored to each state’s regulatory requirements.
The expansion builds on Zeo ScientifiX’s existing activities in Florida under that state’s 2025 law and is positioned as part of a broader national growth strategy. The company highlights that the new state laws do not constitute U.S. Food and Drug Administration approval and that providers remain responsible for compliance with all applicable federal and state requirements, licensing rules, and standards of care.
Zeo ScientifiX, Inc. (ZEOX) filed a Form 12b-25 to notify regulators of a late filing of its Quarterly Report on Form 10-Q for the quarter ended July 31, 2026. The company states that compiling, disseminating and reviewing the information required for the report could not be completed by September 14, 2026 without undue hardship and expense.
Zeo ScientifiX indicates that it expects to file the delayed Form 10-Q within the five-calendar-day extension period permitted for a late quarterly report.
Zeo ScientifiX, Inc. (ZEOX) reported that it has announced the faculty and guest speaker lineup for its inaugural ZEO Xperience, a three-day immersive regenerative medicine educational event for healthcare professionals. The program will be held October 23–25, 2026 at Pier Sixty-Six Resort + Marina in Fort Lauderdale, Florida, with multidisciplinary experts spanning clinical specialties, regulatory law, regenerative science, and healthcare business. The event extends the company’s physician-education platform, which also includes Master Classes, webinars, scientific programming, and clinical collaborations, and is intended to foster direct interaction and knowledge-sharing among attendees and faculty.
ZEO ScientifiX, Inc. announced the launch of ZEO Xperience, its inaugural three-day immersive educational experience for healthcare professionals focused on regenerative medicine and biologics. The event is scheduled for October 23–25, 2026 at Pier Sixty-Six Resort in Fort Lauderdale, Florida.
ZEO Xperience is structured around three themed days: Science & Innovation, Clinical Training & Practice Growth, and a Biohacking Experience. Programming combines evidence-based scientific education, hands-on clinical training, business development strategies, and wellness technologies, aligning with the company’s mission to advance physician education and responsible adoption of regenerative biologic therapies.
Amendment No. 2 to a Schedule 13D reports that Wendy Grey and Greyt Ventures, LLC are major holders of Zeo Scientifix, Inc. equity. They beneficially own 2,117,500 shares of common stock, including 1,155,000 shares issuable upon exercise of warrants, 87,500 restricted shares vesting on July 14, 2026, and 625,000 shares issuable upon exercise of options.
This position represents 23.88% of the common stock class, based on 7,837,441 shares outstanding as of June 12, 2026 and giving effect to the warrants and options. The reporting person also holds 50 shares of Series C Preferred Stock, providing an additional 25.5% of total voting power, for aggregate voting power of 49.38%. The reporting person has sole voting and dispositive power over all 2,117,500 common shares.
The additional interests disclosed arise from equity compensation: restricted stock issued on January 14, 2026 and options granted on June 10, 2026 under the issuer’s 2021 Equity Incentive Plan. The reporting person states no current plans for acquisitions, dispositions, or corporate actions beyond ordinary-course possibilities and potential future equity awards.
Zeo Scientifix, Inc. insider Ian T. Bothwell filed an amendment updating his ownership in the company’s common and Series C preferred stock. He beneficially owns 1,820,094 common shares, representing 20.6% of the common stock after giving effect to his warrants and options, based on 7,837,441 shares outstanding as of June 12, 2026.
His holdings include restricted stock, warrants and options, including a new grant of options for 625,000 shares on June 10, 2026 under the 2021 Equity Incentive Plan. Bothwell also holds 50 Series C Preferred shares that provide an additional 25.5% of total voting power, giving him aggregate voting power of 46.1%. He reports sole voting and dispositive power over his common shares and states he has no definite plans for significant acquisitions, dispositions or corporate control changes.
George Shapiro, M.D. filed Amendment No. 1 to a Schedule 13G reporting his beneficial ownership in Zeo Scientifix, Inc. common stock. He reports beneficially owning 1,311,271 shares of common stock, representing 15.1% of the class. These percentages are based on 7,837,441 shares outstanding as of June 12, 2026, as reported by the company. Shapiro has sole voting and sole dispositive power over all 1,311,271 shares, with no shared voting or dispositive power.
ZEO ScientifiX, Inc. describes new efforts to strengthen its role within South Florida’s healthcare innovation ecosystem. On July 21, 2026, the company highlighted regenerative biologic research and development, physician education, and scientific collaboration as core focus areas, operating from Nova Southeastern University’s Center for Collaborative Research in Davie, Florida.
The company is expanding physician Master Classes, webinars, scientific programming, professional collaborations, and its Medical Advisory Board to connect emerging regenerative medicine science with clinical practice. ZEO ScientifiX presents these initiatives as supporting meaningful scientific exchange and the responsible advancement of regenerative medicine from a South Florida base.